Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.

NACompletedINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions

Breast CancerMetastatic Breast Cancer

Interventions

BIOLOGICAL

Blood sampling

Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )

Trial Locations (2)

Centre François Baclesse, Caen

Centre Henri BECQUEREL, Rouen

All Listed Sponsors

lead

Centre Francois Baclesse

OTHER